Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 2, 2013, Pages 241-258

  Alijotas Reig, Jaume ^a,b,c   Fernández Figueras, Maria Teresa ^c,d   Puig, Lluís ^c,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Germans Trias i Pujol University Hospital   (Spain)

^e Sant Pau University Hospital   (Spain)

Author keywords

Acrylamides; Adverse reactions; Alginate; Collagen; Dermal fillers; Ethylmethacrylate; Granulomas; Hyaluronic acid; Hydroxylapatite; Methylmethacrylate; Poly L lactic acid; Silicone medical grade; Treatment

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; AGAROSE; ALGINIC ACID; AMINOCAPROIC ACID; BIOMATERIAL; CELLULOSE CARBOXIMETIL; COLLAGEN; DERMAL FILLER; DEXTRANOMERE; DIMETICONE; FAT; GELATIN; HYALURONIC ACID; HYDROXYAPATITE; MACROGOL; MICROSPHERE; PARAFFIN; POLITEF; POLY(ETHYL METHACRYLATE); POLY(METHYL METHACRYLATE); POLYACRYLAMIDE; POLYALKYLIMIDE; POLYETHYLENE GLYCOL DI ACRYLATE; POLYLACTIC ACID; POLYMER; POLYPROLACTONE; POLYVINYL ALCOHOL; POLYVINYLHYDROXIDE; POVIDONE; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ADJUVANT DISEASE; ADVERSE OUTCOME; ALLERGIC REACTION; AMYLOIDOSIS; ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BONE EROSION; ENDOPROSTHESIS; ERYTHEMA; FEMALE; FIBROMYALGIA; FLU LIKE SYNDROME; GENETIC PREDISPOSITION; GRANULOMATOSIS; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LUNG EMBOLISM; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MESENCHYMAL STEM CELL; MYOSITIS; PANNICULITIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SARCOIDOSIS; SCLERODERMA; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; VASCULITIS;

ACRYLAMIDES; ADVERSE REACTIONS; ALGINATE; COLLAGEN; DERMAL FILLERS; ETHYLMETHACRYLATE; GRANULOMAS; HYALURONIC ACID; HYDROXYLAPATITE; METHYLMETHACRYLATE; POLY-L-LACTIC ACID; SILICONE MEDICAL GRADE; TREATMENT;

BIOCOMPATIBLE MATERIALS; EDEMA; GRANULOMA; HUMANS; PROSTHESES AND IMPLANTS;

EID: 84886098804     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.02.001     Document Type: Article

References (233)

1. American Society for Aesthetic Plastic Surgery. Cosmetic National Data Bank 2009 Statistics. New York, NY, 2009. ¡Error! Referencia de hipervínculo no válida [accessed 20.01.11].
2. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004, 3:2-15.
3. Ellis D.A., Makdessian A.S., Brown D.J. Survey of future injectables. Facial Plast Surg Clin North Am 2001, 9:405-411.
4. Engelman D.E., Bradley B., Glodberg D.J. Dermal fillers: complications and informed consent. J Cosmet Laser Ther 2005, 7:29-32.
5. Andre P., Lowe N.J., Parc A., Clerici T.H., Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther 2005, 7:171-176.
6. Bergeret-Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 2004, 24:33-46.
7. Alijotas-Reig J., Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long term follow-up and review of the literature. J Eur Acad Dermatol Venereol 2008, 22:150-161.
8. Alijotas-Reig J., Garcia-Gimenez V., Schwartz S.J. Late-onset immune-mediated adverse effects related to polyalkylimide dermal fillers. Arch Dermatol 2008, 144:637-642.
9. Alijotas-Reig J., Garcia-Gimenez V., Miró-Mur F., Vilardell-Tarrés M. Delayed immune-mediated adverse effects related to polyacrylamide dermal fillers: clinical findings, management, and follow-up. Dermatol Surg 2009, 35:360-366.
10. Alijotas-Reig J., Garcia-Gimenez V., Vilardell-Tarres M. Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology 2009, 219:303-308.
11. Descamps V., Landry J., Francés C., Marinho E., Ratziu V., Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology 2008, 217:81-84.
12. Hirsch R., Stier M. Complications of soft tissue augmentation. J Drugs Dermatol 2008, 7:841-845.
13. Requena C., Izquierdo M.J., Navarro M., Martinez A., Vilalta J.J., Botella R., et al. Adverse reactions to injectable aesthetic microimplants. Am J Dermatopathol 2001, 23:197-202.
14. Christensen L., Breiting V., Jansen M., Vuust J., Hogdall E. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 2005, 29:34-48.
15. Duranti F., Salti G., Bovani B., Calandri M., Rosati M. Injectable hyaluronic acid gel for for soft tissue augmentation. Dermatol Surg 1998, 24:1317-1325.
16. Kottke-Marchant K., Anderson J.M., Rabinovitch A. The platelet reactivity of vascular graft prostheses. Biomaterials 1986, 7:441-448.
17. Gordon M., Bullough P.G. Synovial and osseous inflammation in failed silicon-rubber prostheses. J Bon Joint Surg Am 1982, 64:574-580. [other papers].
18. Yates S.G., Nakagawa Y., Berger K., Sauvage L.R. Surface thrombogenicity of arterial prostheses. Surg Gynecol Obstet 1973, 136:12-16.
19. Behling C.A., Spector M. Quantitative characterization of cells at the interface of long term implants of selected polymers. J Biomed Mater Res 1986, 20:653-656.
20. Domansky E.J., Owsley J.Q. Histological investigation of the etiology of capsule contracture following augmentation mammoplasty. Plast Reconstr Surg 1976, 58:689-693.
21. Narins R.S., Brandt F., Leyden J., Lorenc Z.P., Rubin M., Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003, 29:588-595.
22. Sadove R. Injectable poly-L-lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. Aesthetic Plast Surg 2009, 33:113-116.
23. Jansen D.A., Graivier M.H. Evaluation of a calcium hydroxylapatite based implant (Radiesse) for facial soft tissue augmentation. Plast Reconstr Surg 2006, 118(3 Suppl.):S22-S30.
24. Brody H.J. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005, 31:893-897.
25. Lemperle G., Romano J.J., Busso M. Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003, 29:573-587.
26. Lemperle G., Gauthier-Hazan N., Wolters M. Complications after dermal fillers and their treatment. Handchir Mikrochir Plast Chir 2006, 38:354-369. [in German].
27. Park T.H., Seo S.W., Kim J.K., Chang C.H. Clinical experience with hyaluronic acid-filler complications. J Plast Reconstr Aesthet Surg 2011, 64(7):892-896. [Epub 2011 Feb 9].
28. Matarasso S.L. Injectable collagens: lost but not forgotten-a review of products, indications, and injection techniques. Plast Reconstr Surg 2007, 120(Suppl.):17-26.
29. Georgescu D., Jones Y., McCann J.D., Anderson R.L. Skin necrosis after calciumhydroxylapatite injection into the glabellar and nasolabial folds. Ophthal Plast Reconstr Surg 2009, 25(6):498-499.
30. Schanz S., Schippert W., Ulmer A., Rassner G., Fierlbeck G. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol 2002, 146:928-929.
31. Bachmann F., Erdmann R., Hartmann V., Wiest L., Rzany B. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the injectable filler safety study. Dermatol Surg 2009, 35:1629-1634.
32. Roberts S.A., Arthurs B.P. Severe visual loss and orbital infarction following periorbital astethic poly-L-lactic acid (PLLA) injection. Ophthal Plast Reconstr Surg 2012, 28:e68-e70.
33. Sung M.S., Kim H.G., Woo K.I., Kim Y.D. Ocular ischemia and ischemic oculomotor nerve palsy after vascular embolization of injectable calcium hydroxylapatite filler. Ophthal Plast Reconstr Surg 2010, 26(4):289-291.
34. Alam M., Dover J.S. Management of complications and sequelae with temporary injectable fillers. Plast Reconstr Surg 2007, 120(Suppl. 120):98S-105S.
35. Cohen J.L. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 2008, 34(Suppl. 1):S92-S99.
36. Hirsch R.J., Cohen J.L., Carruthers J.D. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 2007, 33:357-360.
37. Sánchez-Carpintero I., Candelas D., Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifiliogr 2010, 101:381-393.
38. Narins R.S., Jewell M., Rubin M., Cohen J., Strobos J. Clinical conference: management of rare events following dermal fillers-focal necrosis and angry red bumps. Dermatol Surg 2006, 32:426-434.
39. Rousso J.J., Pitman M.J. Enterococcus faecalis complicating dermal filler injection: a case of virulent facial abscesses. Dermatol Surg 2010, 36:1638-1641.
40. Toy B.R., Frank P.J. Outbreak of Mycobacterium abscessus infection after soft tissue augmentation. Dermatol Surg 2003, 29:971-973.
41. Lowe N.J., Maxwell C.A., Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 2005, 31:1616-1625.
42. Sclafani A.P., Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg 2009, 35:1672-1680.
43. Leonhardt J.M., Lawrence N., Narins R.S. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg 2005, 31:577-579.
44. Klein A.W. Skin filling. Collagen and other injectables of the skin. Dermatol Clin 2001, 19:491-508.
45. Shoshani D., Markovitz E., Cohen Y., Heremans A., Goldlust A. Skin test hypersensitivity study of a cross-linked, porcine collagen implant for aesthetic surgery. Dermatol Surg 2007, 33(Suppl. 2):S152-S158.
46. Stolman L.P. To the editor: human collagen reactions. Dermatol Surg 2005, 31(11 Pt 2):1634.
47. André P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004, 18(4):422-425.
48. Friedman P.M., Mafong E.A., Kauvar A.N., Geronemus R.G. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002, 28:491-494.
49. Arron S.T., Neuhaus I.M. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol 2007, 6:167-171.
50. Loewe N.J., Maxwell A., Loewe P., Duick M.G., Shan K. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol 2001, 45:930-933.
51. Micheels P. Human anti-hyaluronic acid antibodies: is it possible?. Dermatol Surg 2001, 27:185-191.
52. Lupton J.R., Alster T.S. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000, 26:135-137.
53. Matarasso S.L., Herwick R. Hypersensitivity reaction to nonanimal stabilized hyaluronic acid. J Am Acad Dermatol 2006, 55:128-131.
54. Fernández-Aceñero M.J., Zamora E., Borbujo J. Granulomatous foreign body reaction against hyaluronic acid: report of a case after lip augmentation. Dermatol Surg 2003, 29:1225-1226.
55. Van Dyke S., Hays G.P., Caglia A.E., Caglia M. Severe acute local reactions to a hyaluronic acid-derived dermal filler. J Clin Aesthet Dermatol 2010, 3:32-35.
56. Bassichis B., Blick G., Conant M., Condoluci D., Echavez M., Eviatar J., et al. Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatol Surg 2012, 38(7 Pt 2):1193-1205.
57. Rossner F., Rossner M., Hartmann V., Erdmann R., Wiest L.G., Rzany B. Decrease of reported adverse events to injectable polylactic acid after recommending an increased dilution: 8-year results from the injectable filler safety study. J Cosmet Dermatol 2009, 8(1):14-18.
58. Beljaards R.C., De Roos K.-P., Bruins F.G. NewFill for skin augmentation: a new filler or failure?. Dermatol Surg 2005, 31(7 Pt 1):772-776.
59. Apikian M., Roberts S., Goodman G.J. Adverse reactions to polylactic acid injections in the periorbital area. J Cosmet Dermatol 2007, 6:95-101.
60. Hamilton D.G., Gauthier N., Robertson B.F. Late-onset, recurrent facial nodules associated with injection of poly-L-lactic acid. Dermatol Surg 2008, 34:123-126.
61. Stewart D.B., Morganroth G.S., Mooney M.A., Cohen J., Levin P.S., Gladstone H.B. Management of visible granulomas following periorbital injection of poly-L-lactic acid. Ophthal Plast Reconstr Surg 2007, 23:298-301.
62. Reszko A.E., Sadick N.S., Magro C.M., Farber J. Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatol Surg 2009, 35(Suppl. 1):380-384.
63. Azizzadeh B. Late-onset infections and granuloma formation after facial polylactic acid (new-fill) injections in women who are heavy smokers. Plast Reconstr Surg 2009, 124:316-317.
64. Nichols B.J., Carpenter J., Hribar K.P., Go J., Rice D.H. Acute parotitis after injection of poly-L-lactic acid for malar augmentation: a case report and review of relevant anatomy. Dermatol Surg 2011, 37(3):381-386. [Epub 2011 Feb 25].
65. Alcalay J., Alcalay R., Gat A., Yorav S. Late-onset granulomatous reaction to Artecoll. Dermatol Surg 2003, 29:859-862.
66. Angus J.E., Affleck A.G., Leach I.H., Millard L.G. Two cases of delayed granulomatou reactions to the cosmetic filler Dermalive, a hyaluronic acid and acrylic hydrogel. Br J Dermatol 2006, 155:1077-1078.
67. Rossner M., Rossner F., Bachmann F., Wiest L., Rzany B. Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethyl methacrylate and ethylmethacrylate with hyaluronic acid. Dermatol Surg 2009, 35:367-374.
68. Fischer J., Metzler G., Schaller M. Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies. Arch Dermatol 2007, 143:507-510.
69. Buck D.W., Alam M., Kim J.Y. Injectable fillers for facial rejuvenation: a review. J Plast Reconstr Aesthet Surg 2009, 62:11-18.
70. Karim R.B., Hage J.J., van Rozelaar L., Lange C.A., Raaijmakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg 2006, 59:1409-1414.
71. Nelson L., Stewart K.J. Early and late complications of polyalkylimide gel (Bio-Alcamid®). J Plast Reconstr Aesthet Surg 2011, 64:401-404.
72. Schelke L.W., van den Elzen H.J., Canninga M., Neumann M.H. Complications after treatment with polyalkylimide. Dermatol Surg 2009, 35(Suppl. 2):1625-1628.
73. Chrastil-LaTowsky B., Wesley N.O., MacGregor J.L., Kaminer M.S., Arndt K.A. Delayed inflammatory reaction to bio-alcamid gel used for soft-tissue augmentation. Arch Dermatol 2009, 145:1309-1312.
74. Akrish S., Dayan D., Taicher S., Adam I., Nagler R.M. Foreign body granulomas after injection of Bio-alcamid for lip augmentation. Am J Otolaryngol 2009, 30:356-359.
75. Ono S., Ogawa R., Hyakusoku H. Complications after polyacrylamide hydrogel injection for soft-tissue augmentation. Plast Reconstr Surg 2010, 126:1349-1357.
76. El-Shafey el-SI Complications from repeated injection or puncture of old polyacrylamide gel implant sites: case reports. Aesthetic Plast Surg 2008, 32:162-165.
77. Narins R.S., Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006, 118(3 Suppl.):77S-84S.
78. Lemperle G., Gauthier-Hazan N., Wolters M., Eisemann-Klein M., Zimmermann U., Duffy D.M. Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes. Plast Reconstr Surg 2009, 123:1842-1863.
79. Lemperle G., Morhenn V., Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg 2003, 27:354-366.
80. Zimmermann U.S., Clerici T.J. The histological aspects of fillers complications. Semin Cutan Med Surg 2004, 23:241-250.
81. Requena L., Requena C., Christensen L., Zimmermann U.S., Kutzner H., Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol 2011, 64:1-34.
82. Ficarra G., Mosqueda-Taylor A., Carlos R. Silicone granuloma of the facial tissues: a report of seven cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 94:65-73.
83. Cosatti M., Fernández Romero D.S., Juri M.C., Malbrán A. Facial angioedema after filler injections. Description of five cases. Medicina 2010, 70:513-517.
84. Wohlrab J., Lueftl M., Marsch W.C. Persistent erythema and edema of the mid third and upper aspect of the face (morbusmorbihan): evidence of hidden immunologic contact urticaria and impaired lymphatic drainage. J Am Acad Dermatol 2005, 52:595-602.
85. Hage J.J., Kanhai R.C., Oen A.L., van Diest P.J., Karim R.B. The devastating outcome of massive subcutaneous injection of highly viscous fluids in male-to-female transsexuals. Plast Reconstr Surg 2001, 107:734-741.
86. Restrepo C.S., Artunduaga M., Carrills J.A., Rivera A.L., Ojeda P., Martinez-Jimenez S., et al. Silicone embolism: report of 10 cases abd review of the literature. J Comput Assist Tomogr 2009, 33:233-237.
87. Ellenbogen R., Rubin L. Injectable fluid silicone therapy: human morbidity and mortality. J Am Med Assoc 1975, 234:308-309.
88. Chen Y., Lu C., Perg R. Silicone fluid-induced pulmonary embolism. Am Rev Respir Dis 1993, 147:1299-1302.
89. Lai Y.F., Chao T.Y., Wong S.L. Acute pneumonitis after subcutaneous injections of silicone for augmentation mammoplasty. Chest 1994, 106:1152-1155.
90. Gurvitis G.E. Silicone pneumonitis after a cosmetic augmentation procedure. N Engl J Med 2006, 354:211-212.
91. Villa A., Sparacio F. Severe pulmonary complications after silicone fluid injection. Am J Emerg Med 2000, 18:336-337.
92. Chastre J., Brun P., Soler P., Basset F., Trouillet J.L., Fagon J.Y., et al. Acute and latent pneumonitis after subcutaneous injections of silicone in transsexual men. Am Rev Respir Dis 1987, 135:236-240.
93. Chastre J., Basset F., Viau F., Dournovo P., Bouchama A., Akesbi A., et al. Acute pneumopathy after subcutaneous silicone injections in transsexual men. N Engl J Med 1983, 308:764-767.
94. Celli B., Textor S., Kovnat D. Adult respiratory distress syndrome following dermal augmentation. Am J Med Sci 1978, 275:81-85.
95. Duong T., Schonfeld A.J., Yungbluth M., Slotten R. Acute pneumopathy in a nonsurgical transsexual. Chest 1998, 113:1127-1129.
96. ABCD. CDC case definition of toxic shock syndrome, 〈〉; [accessed 26.10.11]. http://wonder.cdc.gov.wonder/prevguid/.
97. Holm C., Muhlbauer W. Toxic shock syndrome in plastic surgery patients: case reports and review of the literature. Aesthetic Plast Surg 1998, 22:180-184.
98. Clark R.F., Cantrell F.L., Pacal A., Chen W., Betten D.P. Subcutaneous silicone injection leading to multi-sytem organ failure. Clin Toxicol (Phila) 2008, 46:834-837.
99. Acute renal failure associated with cosmetic soft-tissue filler injections-North Carolina 2007. MMWR Morb Mortal Wkly Rep 2008, 57(17):453-456. CDC.
100. Duffy D.M. Complications of fillers: overview. Dermatol Surg 2005, 31:1226-1233.
101. Lemperle G., Hazan-Gauthier N., Lemeprle M. PMMA microspheres for skin and soft-tissue augmentation. Part II: clinical investigations. Plast Reconstr Surg 1995, 96:627-634.
102. Alijotas-Reig J. Recurrent urticarial vasculitis related to non-animal hyaluronic acid skin filler injection. Dermatol Surg 2008, 35:1-4.
103. Mullins R.J., Richards C., Walker T. Allergic reactions to oral, surgical and topical bovine collagen. Anaphilactic risk for surgeons. Aust N Z J Opthalmol 1996, 4:257-260.
104. Park H.J., Jung K.H., Kim S.Y., Lee J.H., Jeong J.Y., Kim J.H. Hyaluronic acid pulmonary embolism: a critical consequence of an illegal cosmetic vaginal procedure. Thorax 2010, 65:360-361.
105. Farmularo G., Liberati C., Sebastiani G.D., et al. Pulmonary embolism after intra-articular injection of methylprednisolone and hyaluronate. Clin Exp Rheumatol 2001, 19:355.
106. Van Nunen S.A., Gatenby P.A., Basten A. Post-mammoplasty connective tissue diseases. Arthritis Rheum 1982, 25:694-697.
107. Kumagai Y., Abe C., Shiokawa Y. Sclerodrma after cosmetic surgery. Arthritis Rheum 1979, 22:532-537.
108. Spiera R.F., Gibofsky A., Spiera H. Silicone gel filled breast implants and connective tissue disease: an overview. J Rheumatol 1994, 21:239-245.
109. Garcia M.I., Alijotas-Reig J., Mitjavila F., Boliart Y., Vidaller A. Esclerodermia tras implantes mamarios de silicona: a propósito de tres casos. Rev Esp Reumatol 1997, 24:215-219.
110. Alijotas-Reig J., Garcia-Domingo M.I. Silicone and autoimmune diseases. An Med Intern 1998, 15:276-283.
111. Selva-O'Callaghan A., Tura J.M., Grau-Junyent J.M., Labrador-Horrillo M., Solans-Laque R., Alijotas-Reig J.J., et al. Silicone gel filled breast implants and dermatomyositis. Clin Exp Rheumatol 2004, 22:376.
112. Bridges A.J., Conley C., Wang G., Burns D.E., Vasey F.B. A clinical and immunologic evaluation of women with silicone breast implants and symptoms of rheumatic disease. Ann Intern Med 1993, 118:929-937.
113. Houpt K.R., Sontheimer R.D. Autoimmune connective tissue diseases and connective tissue-related illnesses after silicone gel augmentation. J Am Acad Dermatol 1994, 31:626-642.
114. Sanchez-Guerrero J., Colditz G.A., Karlson E.W., Hunter D.J., Speizer F.E., Liang M.H. Silicone breast implants and the risk of connective tissue diseases and symptoms. N Engl J Med 1995, 332:1666-1670.
115. Gabriel S.E., O'Fallon W.M., Kurland L.T., Beard C.M., Wooda J.E., Melton L.J. Risk of connective tissue diseases and other disorders after silicone breast implantation. N Engl J Med 1994, 330:1697-1702.
116. Hochberg M.C., White B., Steen V., Medsger T.A., Weisman M., Wigley F.M. The association of augmentation mammoplasty with systemic sclerosis: preliminary results from a case-control study. Arthritis Rheum 1993, 36(Suppl.):S71.
117. Hennekens C.H., Lee I.M., Cook N.R., Hebert P.R., Karlson E.W., LaMotte F., et al. Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. J Am Med Assoc 1996, 275:616-621.
118. Nyrén O., Yin L., Josefsson S., McLaughlin J.K., Blot W.J., Engqvist M., et al. Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden. Br Med J 1998, 316:417-422.
119. Travis W.D., Balogh K., Abraham J.L. Silicone granulomas: report of three cases and review of the literature. Hum Pathol 1985, 16:19-27.
120. Anderson D.R., Schwartz J., Cottrill C.M., McClain S.A., Ross J.S., Magidson J.G., et al. Silicone granulomas in acral skin in a patient with silicone-gel breast implants and systemic sclerosis. Int J Dermatol 1996, 35:36-38.
121. Teuber S.S., Ito L.K., Anderson M., Gershwin M.E. Silicone breast implants-associated scarring dystrophy of the arm. Arch Dermatol 1995, 131:54-56.
122. Raso D.S., Greene W.B., Harley R.A., Maize J.C. Silicone deposition in reconstruction scars of women with silicone breast implants. J Am Acad Dermatol 1996, 35:32-36.
123. Marcusson J.A., Bjarnason B. Unusual reaction to silicone content in breast implants. Acta Dermatol Venereol 1999, 79:136-138.
124. Alijotas-Reig J., Gracía-Gimenez V., Vilardell-Tarrés M. Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections. Dermatol Surg 2012, 38:38-47.
125. Beer K.R. Radiesse nodule in the lips from a distant injection site: report of a case and consideration of etiology and management. J Drugs Dermatol 2007, 6:846-847.
126. Cheng N.-X., Wang Y.-L., Wang J.-H., Zhang X.-M., Zhong H. Complications of breast augmentation with injected hydrophilic polyacrylamide gel. Aesthetic Plast Surg 2002, 26:375-382.
127. Matarasso S.L. Understanding and using hyaluronic acid. Aesthetic Surg J 2004, 24:361-364.
128. Christensen L., Breiting V., Hodgall E. Adverse reactions following injection with permanent facial filler polyacrylamide hydrogel: causes and treatment. Eur J Plast Surg 2006, 28:464-471.
129. ABCD. Pons-Guiraud A. Materiaux de coubement des rides et des depressions du visage, 〈〉; 2011 [accesed 13.12.11]. http://www-therapeutic-dermatologique.org/print.
130. Cukler J., Beauchamp R.A., Spindler J.S., Spindler S., Lorenzo C., Trentham D.E. Association between bovine collagen dermal implants and a dermatomyositis or a polymyositis-like M30467 syndrome. Ann Intern Med 1993, 118:920-928.
131. Broder K.W., Cohen S.R. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006, 118(3 Suppl.):7S-14S.
132. Bentkover S.H. The biology of facial fillers. Facial Plast Surg 2009, 25:73-85.
133. Doshi N., Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One 2010, 5:e10051.
134. Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg 2007, 33(Suppl. 2):S168-S175.
135. Wiest L.G., Stolz W., Schroeder J.A. Electron microscopic documentation of late changes in permanent fillers and clinical management of granulomas in affected patients. Dermatol Surg 2009, 35(Suppl. 2):1681-1688.
136. Rohrich R.J., Monheit G., Nguyen A.T., Brown S.A., Fagien S. Soft-tissue filler complications: the important role of biofilms. Plast Reconstr Surg 2010, 125:1250-1256.
137. Alijotas-Reig J., Miró-Mur F., Planells-Romeu I., Garcia-Aranda N., Garcia-Gimenez V., Vilardell-Tarrés M. Are bacterial growth and/or chemotaxis increased by filler injections? Implications for the pathogenesis and treatment of filler-related granulomas. Dermatology 2010, 221(4):356-364.
138. Lemperle G., Nicolau P., Scheiermann N. Is there any evidence for biofilms indermal fillers?. Plast Reconstr Surg 2011, 128:84e-85e.
139. Miró-Mur F., Hindié M., Kandhaya-Pillai R., Tobajas V., Schwartz S., Alijotas-Reig J. Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. J Biomed Mater Res B 2009, 90B:510-520.
140. Alijotas-Reig J., Hindié M., Kandhaya-Pillai R., Miró-Mur F. Bioengineered hyaluronic acid elicited a non-antigenic T cell activation: implications from cosmetic medicine and surgery to nanomedicine. J Biomed Mater Res A 2010, 95A:180-190.
141. Christen U., von Herrath G. Infections and autoimmunity. Good or bad?. J Immunol 2005, 174:7481-7486.
142. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 19:1217-1225.
143. Shoenfeld Y., Agmon-Levin N. "ASIA"-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
144. Rose N.R. Autoimmunity, infection and adjuvants. Lupus 2010, 19:354-358.
145. Rsachi E., Borghi M.O., Grossi C., Broggini V., Pierangeli S., Meroni P.L. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008, 17:937-942.
146. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007, 26:1271-1285.
147. Rosner M., Rossner F., Bachmann F., Wiest L., Rzany B. Risk of severe adverse ractions to an injectable filler based on a fixed combination on hydroxylethylmethacrylate and ethylmethycrylate with hyaluronic acid. Dermatol Surg 2009, 35(Suppl. 1):367-374.
148. Bachmann F., Erdmann R., Hartmann V., Becker-Wegerich P., Wiest L., Rzany B. Adverse reactions caused by consecutive injections of different fillers in the same facial region: risk assessment based on the results from the injectable filler safety study. J Eur Acad Dermatol Venereol 2011, 25(8):907-912.
149. Sánchez O., Rodríguez-Sureda V., Domínguez C., Fernández-Figueras M.T., Angel Vilches A., Llurba E., et al. Study of biomaterial-induced macrophage activation, cell-mediated immune response and molecular oxidative damage in patients with dermal bioimplants. Immunobiology 2012, 217:44-53.
150. Fernández-Figueras MT, Alijotas-Reig J, Naranjo L, Musulen E, Miró-Mur F, Schwarts Jr S, et al. Estudio inmunofenotípico y de expresión de HLA em reacciones a implantes cutáneos con fines cosméticos. XXIV Congreso de la Sociedad Española de Anatomía Patológica y XIX Congreso de la Sociedad Española de Citología. Sevilla 20-23 de mayo de; 2009.
151. Klein A.W. Techniques for soft tissue augmentation: an A to Z. Am J Clin Dermatol 2006, 7:107-120.
152. Imagawa K., Ohkum S. A case of fat injection for treating subcutaneous atrophy caused by local administration of corticosteroids. Tokai J Exp Clin Med 2010, 35(2):66-69.
153. Moseley T.A., Min Zhu M., Hedrick H. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg 2006, 118(Suppl.):121S.
154. Oh D.S., Cheon Y.W., Jeon Y.R., Lew D.H. Activated platelet-rich plasma improves fat graft survival in nude mice: a pilot study. Dermatol Surg 2011, 37:619-625.
155. Kakudo N., Minakata T., Mitsui T., Kushida S., Notodihardjo F.Z., Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg 2008, 122:1352-1360.
156. Guisantes V. Injertos de tejido adiposo autólogo en la lipoatrofia facial de pacientes VIH+: Comparación de dos estrategias de tratamiento y utilidad de la tomografía computerizada en la evaluación de su durabilidad. Tesis Doctoral. Universidad de Barcelona; 2010.
157. Sa H.S., Woo K.L., Suh Y.L., Kim Y.D. Periorbital lypogranuloma: a previously unknown complication of autologous fat injections for fascial augmentation. Br J Ophthalmol 2011, 95:1259-1263.
158. Yang W.T., Suen M., Ho W.S., Metreweli C. Paraffinomas of the breast: mammographic, ultrasonographic, and radiographic appearances with clinical and histopathologic correlation. Clin Radiol 1966, 51:130-133.
159. Gu D.H., Yoon D.Y., Chang S.K., Lim K.J., Cha J.H., Seo Y.L., et al. CT features of foreign body granulomas after cosmetic paraffin injection into the cervicofacial area. Diagn Interv Radiol 2010, 16:125-128.
160. Brooks N. A foreign body granuloma produced by an injectable collagen implant at a test site. J Dermatol Surg Oncol 1982, 8:111-114.
161. Overholt M.A., Tschen J.A., Font R.L. Granulomatous reaction to collagen implant: light and electron microscopic observations. Cutis 1993, 51:95-98.
162. Barr R.J., Stegman S.J. Delayed skin test reaction to injectable collagen implant (Zyderm). The histopathologic comparative study. J Am Acad Dermatol 1984, 10:652-658.
163. Hanke C.W., Hingley H.R., Jolivette D.M., Swanson N.A., Stegman S.J. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol 1991, 25:319-326.
164. Narins S., Beer Kenneth Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006, 118(Suppl.):77S.
165. Shvartsbeyn M., Rapkiewicz A. Silicon-associated subcutaneous lesion presenting as a mass: a confounding histopathologic correlation. Hum Pathol 2011, 42:1364-1367.
166. Shafir R., Amir A., Gur E. Long-term complications of facial injections with Restylane (injectable hyaluronic acid). Plast Reconstr Surg 2000, 106:1215-1216.
167. Rongioletti F., Cattarini G., Sottofattori E., Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 2003, 139:815-816.
168. Descamps V., Landry J., Frances C., Marinho E., Ratziu V., Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology 2008, 217:81-84.
169. Moulonguet I., de Goursac C., Plantier F. Granulomatous reaction after injection of a new resorbable filler novabel. Am J Dermatopathol 2011, 33:710-711.
170. Huh S.Y., Cho S., Kim K.H., An J.S., Won C.H., Chang S.E., et al. A case of complication after Matridex(R) injection. Ann Dermatol 2010, 22:81-84.
171. Massone C., Horn M., Kerl H., Ambros-Rudolph C.M., Giovanna Brunasso A.M., Cerroni L. Foreign body granuloma due to Matridex injection for cosmetic purposes. Am J Dermatopathol 2009, 31:197-199.
172. Sampson H.A., Muñoz-Furlong A., Campbell R.L., Adkinson N.F., Bock S.A., Branum A., et al. Second symposium on the definition and management of anaphylaxis: report-Second National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 17:391-397.
173. Lemperle G., Gauthier-Hazan N. Foreign body granulomas after all injectable dermal fillers: part 2, treatment options. Plast Reconstr Surg 2009, 123:1864-1873.
174. ABCD. Bio-Alcamid, the injectable prosthesis. Manufacturer information. Polymekon Research (material reserved for physicians-Ref. 920; 2003. p. 1-13.
175. Lambros V. The use of hyaluronidase to reverse the effects of hyaluronic acid fillers. Plast Reconstr Surg 2004, 114:277.
176. Vedamurthy M. Soft tissue augmentation-use of hyaluronic acid as dermal filler. Indian J Dermatol Venerol Leprol 2004, 70:383-387.
177. Soparkar C.N., Patrinely J.R. Managing inflammatory reaction to Restylane. Ophthal Plast Reconstr Surg 2005, 21:151-153.
178. Van Dick S., Hays G.P., Caglia A.E., Caglia M. Severe acute local reactions to hyaluronic acid derived dermal fillers. J Clin Aesthet Dermatol 2010, 3:32-35.
179. Borchard K., Puy R., Nixon R. Hyaluronidase allergy: a rare cause of periorbital inflammation. Australas J Dermatol 2010, 51:49-51.
180. Lee A., Grummer S.E., Kriegel D., Marmur E. Hyaluronidase. Dermatol Surg 2010, 36:1071-1077.
181. Xiong Z., Ohlfest J.R. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunother 2011, 34:264-269.
182. Gaspari A., Tyring S.K., Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009, 8:467-474.
183. Baunamann L., Halem M. Lip silicone granulomas foreign body reactions. Treatment with Aldara (imiquimod 5%). Dermatol Surg 2003, 29:429-432.
184. Glashofer M.D., Cohen J.L. Complications from soft-tissue augmentation of the face: a guide to understanding, avoiding, and managing periprocedured issues. Injectable fillers. Principles and practice 2010, 121-139. Wiley-Blackwell, Oxford. J. Derek (Ed.).
185. Kumar B., Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex Transm Infect 2011, 87:432.
186. Anadkat M.J., Bogucki B.A. Development of adenopathy during the use of topical imiquimod. J Am Acad Dermatol 2011, 64:e75-e77.
187. Santos-Juanes J., Esteve A., Mas-Vidal A., Coto-Segura P., Salgueiro E., Gómez E., et al. Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology 2011, 222:109-112.
188. Chan M.P., Zimarowski M.J. Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases. Am J Dermatopathol 2011, 33:523-527.
189. Sherman R.N. Avoiding dermal filler complications. Clin Dermatol 2009, 27:S23-S32.
190. Rongioletti F. Exogenous cutaneous deposits with special consideration to skin reactions to soft tossue fillers. Clinical and pathological aspects of skin diseases in endocrine, metabolic, nutritional and deposition diseases 2010, 181-189. Springer, New York. F. Rongioletti, B.R. Smoller (Eds.).
191. James D.G., Williams W.J. Sarcoidosis and other granulomatous disorders. Major problems in internal medicine 1985, 24:1-254. W.B. Saunders Co, Philadelphia.
192. Rynes R.I. Antimalarial drugs. Textbook of rheumatology 1993, 731-742. W.B. Saunders, Philadelphia. 4th ed. W.N. Kelley, E.D. Harris, S. Ruddyn, C.B. Sledge (Eds.).
193. Wozniacka A., Lesiak A., Narbutt J., McCauliffe D.P., Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cyine level in systemic lupus erythematosus patients. Lupus 2006, 15:268-275.
194. Antonovic D., Callen J. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005, 141:869-872.
195. Vedamurthy M. Soft tissue augmentation-Use of hyaluronic acid as dermal filler. Indian J Dermatol Venerol Leprol 2004, 70:383-387.
196. Simons F.E.R. Advances in H1-antihistamines. N Engl J Med 2004, 351:2203-2217.
197. Boone M., Lespagnard L., Renard N., Song M., Rihoux J.P. Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine. J Eur Acad Dermatol Venereol 2000, 14:263-266.
198. Ashenager M.S., Grgela T., Aragane Y., Kawada A. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol 2007, 17:20-26.
199. Park C.S., Cho J.H., Kang J.M., Kim B.K., Han M.A. Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP). Auris Nasus Larynx 2011, 38:474-479.
200. Tsai T.F., Yeh T.Y. Allopurinol in dermatology. Am J Clin Dermatol 2010, 11(4):225-232.
201. Reisemberger E.M., Landthaler M., Wiest I., et al. Foreign body granulomascaused by polymethtylmethacrylate microspheres: successful treatment with allopurinol. Arch Dermatol 2003, 139:17-20.
202. Redondo P., Del Olmo J., Alberola I. In situ and distant foreign body granulomas caused by silicone. Treatment with allopurinol. Br J Dermatol 2005, 152:1064-1065.
203. Ficcara G., Mosqueda-taylor A., Carlos R. Silicone granuloma of the facial tissues: a report of seven cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 94:65-73.
204. Senet P., Bachelez H., Ollivaud L., et al. Minocicline for the treatment of cutaneous silicone granulomas. Br J Dermatol 1999, 140:985-987.
205. Bachelez H., Senet P., Cadranel J., et al. The use of tetraciclines for the treatment of sarcoidosis. Arch Dermatol 2001, 137:69-73.
206. Cocco G., Chu D.C., Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010, 21:503-508.
207. Aivaliotis M., Kontochristopoulos G., Hatziolou E., Aroni K., Zakopoulou N. Successful colchicine administration in facial granulomas caused by cosmetic implants: report of a case. J Dermatolog Treat 2007, 18:112-114.
208. Marques-da-Silva C., Chaves M.M., Castro N.G., Coutinho-Silva R., Guimaraes M.Z. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 2011, 163:912-926.
209. Hall J.A., Grainger J.R., Spencer S.P., Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity 2011, 35(1):13-22.
210. Plewig G., Wagner A. Anti-inflammatory effects of 13-cis-retinoic acid: an in vivo study. Arch Dermatol Res 1981, 270:89-94.
211. Gollinck H. New indications and new retinoics. Dermatologica 1987, 175(Suppl. 1):182-195.
212. Lloret P., España A., Leache A., Bauzá A., Fernández-Galar M., Idoate M.A., et al. Successful treatment of granulomatous reactions secondary to injection of esthetic implants. Dermatol Surg 2005, 31:486-490.
213. Jansen T., Kossmann E., Plewig G. Silikonome, ein interdiszilinäres problem. Hautarzt 1993, 44:636-643. [ in German].
214. Liu J., Farmer J., Lane W., Friedman J., Weissman I., Schreiber S. Calcineurin is a common target of cyclophilin-cyclosporin A and FK506 complexes. Cell 1991, 66:807.
215. Thomson A.W., Bonham C.A., Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995, 17:584-591.
216. Baumann L.S., Kerdel F. The treatment of bovine collagen allergy with cyclosporin. Dermatol Surg 1999, 25:247-248.
217. Lemperle G., Rullan P.P., Gauthier-Hazan N. Avoiding and treating dermal filler complicatons. Plast Reconstr Surg 2006, 118(Suppl. 3):92S-107S.
218. Gibbons L.J., Hyrich K.L. Biologic therapy for rheumatoid arthritis: clinical fficacy and predictors of response. BioDrugs 2009, 23:111-124.
219. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193. BIOGEAS Study Group.
220. Ramos-Casals M., Brito-Zerón P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
221. Díaz-Lagares C., Pérez-Alvarez R., García-Hernández F.J., Ayala-Gutiérrez M.M., Callejas J.L., Martínez-Berriotxoa A., et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011, 13:R112.
222. Ribera M., Leal L., Luelmo J. Etanercept and infections. Actas Dermosifiliogr 2010, 101(Suppl. 1):70-76.
223. Pasternak F.R., Fox L.P., Engler D.E. Silicone granulomas treated with etanercept. Arch Dermatol 2005, 141:13-15.
224. Gutmann C. Silicone granuloma management: TNF inhibitors may be effective as intervention. Dermatol Times 2003, 75-76.
225. Desai A.M., Browning J., Rosen T. Etanercept therapy for silicone granuloma. J Drugs Dermatol 2006, 5:894-896.
226. Rapaport M.J. Silicone granulomas treated with etanercept. Arch Dermatol 2005, 141(9):1171.
227. Broder K.W., Cohen S.R. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006, 118(Suppl.):7S-14S.
228. Sperling B., Bachmann F., Hartmann V., Erdmann R., Wiest L., Rzany B. The current state of treatment of adverse reactions to injectable fillers. Dermatol Surg 2010, 36:1895-1904.
229. Hruza G.J., Ammirati L.T. Granuloma faciale treated with 595-nm pulsed dye laser. Dermatol Surg 2011, 37:1060-1061.
230. Pohl L., Karsai S., Raulin C. Recurrent pyogenic granulomas. Treatment at difficult anatomic sites with the pulsed Nd: YAG laser (1064-nm). Hautarzt 2011, 62:46-50. [in German].
231. Cassuto D., Marangoni O., De Santis G., Christensen L. Advanced laser techniques for filler-induced complications. Dermatol Surg 2009, 35(Suppl. 2):1689-1695.
232. Hanke C.W., Rohrich R.J., Busso M., Carruthers A., Carruthers J., Fagien S., et al. Facial soft-tissue fillers: assessing the state of the science conference proceedings report. J Am Acad Dermatol 2011, 64(4 Suppl.):S53-S65.
233. Rohrich R.J., Hanke C.W., Busso M., Carruthers A., Carruthers J., Fagien S., et al. Facial soft-tissue fillers conference: assessing the state of the science. Plast Reconstr Surg 2011, 127(4 Suppl.):22S-25S.